Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 2Brain Neoplasms 2Thyroid Neoplasms 1Glioblastoma 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

Temozolomide 14Radiotherapy 14Carboplatin 7Irinotecan 6Everolimus 5Filgrastim 4Carmustine 4Surgical Procedures, Operative 3Radiation 3Paclitaxel 3Ifosfamide 3selpercatinib 2pembrolizumab 2Trastuzumab 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Methotrexate 2Imatinib Mesylate 2IL13-PE38 2Dasatinib 2Chemotherapy, Adjuvant 2Bevacizumab 2vitespin 1veliparib 1vatalanib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1tipifarnib 1terameprocol 1temsirolimus 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Central Nervous System Neoplasms × alectinib × Clear all
NCT04774718 2026-06-04

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Hoffmann-La Roche

Phase 1/2 Recruiting
42 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡